Can we prevent, reduce or reverse intestinal fibrosis in IBD?

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 10, 2013, Pages 1283-1304

  Latella, G ^a   Sferra, R ^a   Speca, S ^a   Vetuschi, A ^a   Gaudio, E ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti fibrotic agents; Crohn's disease; Inflammatory bowel disease; Intestinal fibrosis; Therapy; Ulcerative colitis

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; ADALIMUMAB; ANTIBIOTIC AGENT; ANTIFIBROTIC AGENT; AZATHIOPRINE; CAPTOPRIL; CERTOLIZUMAB PEGOL; CHEMOKINE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; DASATINIB; EVEROLIMUS; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LOSARTAN; MERCAPTOPURINE; MESALAZINE; MESSENGER RNA; METHOTREXATE; NATALIZUMAB; NILOTINIB; RAPAMYCIN; SALICYLIC ACID; SIMVASTATIN; STEROID;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BALLOON DILATATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CROHN DISEASE; DRUG EFFICACY; ENTERITIS; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROGENESIS; HUMAN; INTESTINAL FIBROSIS; INTESTINE RESECTION; MESENCHYME CELL; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STENT; STRICTUREPLASTY; SURGICAL TECHNIQUE; TREATMENT RESPONSE; WOUND HEALING;

EXTRACELLULAR MATRIX; FIBROSIS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; PPAR GAMMA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84878535737     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (183)

1. SCHIRBEL A, FIOCCHI C. Inflammatory bowel disease: Established and evolving considerations on its etiopathogenesis and therapy. J Dig Dis 2010; 11: 266-276.
2. ABRAHAM C, CHO JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-2078.
3. COSNES J, GOWER-ROUSSEAU C, SEKSIK P, CORTOT A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785-1794.
4. LATELLA G, PAPI C. Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol 2012; 18: 3790-3799.
5. RIEDER F, KARRASCH T, BEN-HORIN S, SCHIRBEL A, EHEHALT R, WEHKAMP J, DE HAAR C, VELIN D, LATELLA G, SCALDAFERRI F, ROGLER G, HIGGINS P, SANS M. Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing. J Crohns Colitis 2012; 6: 373-385.
6. SPECA S, GIUSTI I, RIEDER F, LATELLA G. Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol 2012; 18: 3635-3661.
7. BURKE JP, MULSOW JJ, O'KEANE C, DOCHERTY NG, WATSON RW, O'CONNELL PR. Fibrogenesis in Crohn's disease. Am J Gastroenterol 2007; 102: 439-448.
8. RIEDER F, FIOCCHI C. Intestinal fibrosis in inflammatory bowel disease-Current knowledge and future perspectives. J Crohns Colitis 2008; 2: 279-290.
9. RIEDER F, FIOCCHI C. Intestinal fibrosis in IBD-a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol 2009; 6: 228-235.
10. RIEDER F, SCHIRBEL A, OUYGAN Z, WEST G, RHO H, DE LA MOTTE C, FIOCCHI C. Pro-fibrogenic activity of Toll-like receptor (TLR) and NOD-Like Receptor (NLR) ligands on Human Intestinal Myofibroblasts (HIF)-linking bacterial innate immunity to intestinal fibrosis. Gastroenterology 2010; 138: S-35.
11. GAZOULI M, PACHOULA I, PANAYOTOU I, MANTZARIS G, CHROUSOS G, ANAGNOU NP, ROMA-GIANNIKOU E. NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease. World J Gastroenterol 2010; 16: 1753-1758.
12. DUBINSKY MC, KUGATHASAN S, MEI L, PICORNELL Y, NEBEL J, WROBEL I, QUIROS A, SILBER G, WAHBEH G, KATZIR L, VASILIAUSKAS E, BAHAR R, OTLEY A, MACK D, EVANS J, ROSH J, HEMKER MO, LELEIKO N, CRANDALL W, LANGTON C, LANDERS C, TAYLOR KD, TARGAN SR, ROTTER JI, MARKOWITZ J, HYAMS J; WESTERN REGIONAL PEDIATRIC IBD RESEARCH ALLIANCE; PEDIATRIC IBD COLLABORATIVE RESEARCH GROUP; WISCONSIN PEDIATRIC IBD ALLIANCE. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008; 6: 1105-1111.
13. RIEDER F, LAWRANCE IC, LEITE A, SANS M. Predictors of fibrostenotic Crohn's disease. Inflamm Bowel Dis 2011; 17: 2000-2007.
14. LUNA J, MASAMUNT MC, LAWRANCE IC, SANS M. Mesenchymal cell proliferation and programmed cell death: key players in fibrogenesis and new targets for therapeutic intervention. Am J Physiol Gastrointest Liver Physiol 2011; 300: G703-G708.
15. ANGELUCCI E, CESARINI M, GENTILE P, NECOZIONE S, FIERI G, CAPRILLI R, LATELLA G. Available medical therapies do not affect development of major complications and need for surgery in Crohn's isease: Long-term prospective study on a population of 193 consecutive patients. J Crohns Colitis 2011; 5: S120-S121.
16. COSNES J, NION-LARMURIER I, BEAUGERIE L, AFCHAIN P, TIRET E, GENDRE JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-241.
17. SPINELLI A, CORREALE C, SZABO H, MONTORSI M. Intestinal fibrosis in Crohn's disease: medical treatment or surgery? Curr Drug Targets 2010; 11: 242-248.
18. FIOCCHI C, LUND PK. Themes in fibrosis and gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2011; 300: G677-G683.
19. MIFFLIN RC, PINCHUK IV, SAADA JI, POWELL DW. Intestinal myofibroblasts: targets for stem cell therapy. Am J Physiol Gastrointest Liver Physiol 2011; 300: G684-G696.
20. PUCILOWSKA JB, WILLIAMS KL, LUND PK. FIBROGENESIS IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastroinest Liver Physiol 2000; 279: G653-G659.
21. WYNN TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210.
22. POWELL DW, MIFFLIN RC, VALENTICH JD, CROWE SE, SAADA JI, WEST AB. Myofibroblasts I. Paracrine cells important in health and disease. Am J Physiol Cell Physiol 1999; 277: C1-C9.
23. POWELL DW, MIFFLIN RC, VALENTICH JD, CROWE SE, SAADA JI, WEST AB. Myofibroblasts II. Intestinal subepithelial myofibroblasts. Am J Physiol Cell Physiol 1999; 277: C183-C201.
24. SANDERS KM, ORDÖG T, WARD SM. Physiology and pathophysiology of the interstitial cells of Cajal: from bench to bedside. IV. Genetic and animal models of GI motility disorders caused by loss of interstitial cells of Cajal. Am J Physiol Gastrointest Liver Physiol 2002; 282: G747-G756.
25. VETUSCHI A, SFERRA R, LATELLA G, D'ANGELO A, CATITTI V, ZANNINELLI G, CONTINENZA MA, GAUDIO E. Smad3-null mice lack interstitial cells of Cajal in the colonic wall. Eur J Clin Invest 2006; 36: 41-48.
26. WYNN TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117: 524-529.
27. NG EK, PANESAR N, LONGO WE, SHAPIRO MJ, KAMINSKI DL, TOLMAN KC, MAZUSKI JE. Human intestinal epithelial and smooth muscle cells are potent producers of IL-6. Mediators Inflamm 2003; 12: 3-8.
28. KNITTEL T, KOBOLD D, SAILE B, GRUNDMANN A, NEUBAUER K, PISCAGLIA F, RAMADORI G. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 1999; 117: 1205-1221.
29. APTE, M. HABER PS, DARBY SJ, RODGERS SC, MCCAUGHAN GW, KORSTEN MA, PIROLA RC, WILSON JS. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut 1999; 44: 534-541.
30. RIEDER F, FIOCCHI C. Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Curr Opin Gastroenterol 2008; 24: 462-468.
31. GERHARDT H, BETSHOLTZ C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003; 314:15-23.
32. FLIER SN, TANJORE H, KOKKOTOU EG, SUGIMOTO H, ZEISBERG M, KALLURI R. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem 2010; 285: 20202-20212.
33. RIEDER F, KESSLER SP, WEST GA, BHILOCHA S, DE LA MOTTE C, SADLER TM, GOPALAN B, STYLIANOU E, FIOCCHI C. Inflammation-induced endothelial-to- mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol 2011; 179: 2660-2673.
34. UMAR S. Intestinal stem cells. Curr Gastroenterol Rep 2010; 12: 340-348.
35. ISHII G, SANGAI T, SUGIYAMA K, ITO T, HASEBE T, ENDOH Y, MAGAE J, OCHIAI A. In vivo characterization of bone marrow-derived fibroblasts recruited into fibrotic lesions. Stem Cells 2005; 23: 699-706.
36. QUAN TE, COWPER SE, BUCALA R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 2006; 8: 145-150.
37. VON LAMPE B, BARTHEL B, COUPLAND SE, RIECKEN EO, ROSEWICZ S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000; 47: 63-73.
38. RAVI A, GARG P, SITARAMAN SV. Matrix metalloproteinases in inflammatory bowel disease: boon or a bane? Inflamm Bowel Dis 2007; 13: 97-107.
39. MEIJER MJ, MIEREMET-OOMS MA, VAN HOGEZAND RA, LAMERS CB, HOMMES DW, VERSPAGET HW. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol 2007; 13: 2960-2966.
40. DERYNCK R, ZHANG YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003; 425: 577-584.
41. ROBERTS AB, RUSSO A, FELICI A, FLANDERS KC. Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta. Ann NY Acad Sci 2003; 995: 1-10.
42. BABYATSKY MW, ROSSITER G, PODOLSKY DK. Expression of transforming growth factor alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996; 110: 975-984.
43. FICHTNER-FIEGL S, STROBER W, GEISSLER EK, SCHLITT HJ. Cytokines mediating the induction of chronic colitis and colitis-associated fibrosis. Mucosal Immunol 2008; 1: S24-S27.
44. RIEDER F, KESSLER S, SANS M, FIOCCHI C. Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. Am J Physiol Gastrointest Liver Physiol 2012; 303: G786-G801.
45. VALLANCE BA, GUNAWAN MI, HEWLETT B, BERCIK P, VAN KAMPEN C, GALEAZZI F, SIME PJ, GAULDIE J, COLLINS SM. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol 2005; 289: G116-G128.
46. ZANNINELLI G, VETUSCHI A, SFERRA R, D'ANGELO A, FRATTICCI A, CONTINENZA MA, CHIARAMONTE M, GAUDIO E, CAPRILLI R, LATELLA G. Smad3 knock-out mice as a useful model to study intestinal fibrogenesis. World J Gastroenterol 2006; 12: 1211-1218.
47. LATELLA G, VETUSCHI A, SFERRA R, ZANNINELLI G, D'ANGELO A, CATITTI V, CAPRILLI R, FLANDERS KC, GAUDIO E. Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid-induced colorectal fibrosis. Eur J Clin Invest 2009; 39: 145-156.
48. LAKOS G, TAKAGAWA S, CHEN SJ, FERREIRA AM, HAN G, MASUDA K, WANG XJ, DIPIETRO LA, VARGA J. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004; 165: 203-217.
49. ZHAO J, SHI W, WANG YL, CHEN H, BRINGAS P JR, DATTO MB, FREDERICK JP, WANG XF, WARBURTON D. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2002; 282: L585-L593.
50. INAZAKI K, KANAMARU Y, KOJIMA Y, SUEYOSHI N, OKUMURA K, KANEKO K, YAMASHIRO Y, OGAWA H, NAKAO A. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int 2004; 66: 597-604.
51. LATELLA G, VETUSCHI A, SFERRA R, CATITTI V, D'ANGELO A, ZANNINELLI G, FLANDERS KC, GAUDIO E. Targeted disruption of Smad3 confers resistance to the development of DMN-induced hepatic fibrosis in mice. Liver Int 2009, 29: 997-1009.
52. FUKASAWA H, YAMAMOTO T, TOGAWA A, OHASHI N, FUJIGAKI Y, ODA T, UCHIDA C, KITAGAWA K, HATTORI T, SUZUKI S, KITAGAWA M, HISHIDA A. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci USA 2004; 101: 8687-8692.
53. DOOLEY S, HAMZAVI J, BREITKOPF K, WIERCINSKA E, SAID HM, LORENZEN J, TEN DIJKE P, GRESSNER AM. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003; 125: 178-191.
54. DONG C, ZHU S, WANG T, YOON W, LI Z, ALVAREZ RJ, TEN DIJKE P, WHITE B, WIGLEY FM, GOLDSCHMIDT-CLERMONT PJ. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002; 99: 3908-3913.
55. NAKAO A, FUJII M, MATSUMURA R, KUMANO K, SAITO Y, MIYAZONO K, IWAMOTO I. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999; 104: 5-11.
56. LATELLA G, ZANNINELLI G. Prevention and treatment of intestinal fibrosis: up-regulate smad7 or inhibit smad3 expression. Eur J Clin Invest 2008; 38: 878-880.
57. DI SABATINO A, JACKSON CL, PICKARD KM, BUCKLEY M, ROVEDATTI L, LEAKEY NA, PICARIELLO L, CAZZOLA P, MONTELEONE G, TONELLI F, CORAZZA GR, MACDONALD TT, PENDER SL. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut 2009; 58: 777-789.
58. MUNZ B, HÜBNER G, TRETTER Y, ALZHEIMER C, WERNER S. A novel role of activin in inflammation and repair. J Endocrinol 1999; 161: 187-193.
59. WERNER S, ALZHEIMER C. Roles of activin in tissue repair, fibrosis, and inflammatory disease. Cytokine Growth Factor Rev 2006; 17: 157-171.
60. GROTENDORST GR. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 1997; 8: 171-179.
61. BLOM IE, GOLDSCHMEDING R, LEASK A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol 2002; 21: 473-482.
62. KUMAGAI S, OHTANI H, NAGAI T, FUNA K, HIWATASHI NO, SHIMOSEGAWA, NAGURA H. Platelet-derived growth factor and its receptors are expressed in areas of both active inflammation and active fibrosis in inflammatory bowel disease. Tohoku J Exp Med 2001; 195: 21-33.
63. BONNER JC. REGULATION OF PDGF AND ITS RECEPTORS IN FIBROTIC DISEASES. Cytokine Growth Factor Reviews 2004; 15: 255-273.
64. SIMMONS JG, LING Y, WILKINS H, FULLER CR, D'ERCOLE AJ, FAGIN J, LUND PK. Cell-specific effects of insulin receptor substrate-1 deficiency on normal and IGF-I-mediated colon growth. Am J Physiol Gastrointest Liver Physiol 2007; 293: G995-G1003.
65. ZIMMERMANN EM, LI L, HOU YT, MOHAPATRA NK, PUCILOWSKA JB. Insulin-like growth factor I and insulinlike growth factor binding protein 5 in Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2001; 280: G1022-G1029.
66. GIELING RG, WALLACE K, HAN YP. Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1324-G1331.
67. LIU X. Inflammatory cytokines augments TGFbeta1-induced epithelial-mesenchymal transition in A549 cells by up-regulating TbetaR-I. Cell Motil Cytoskeleton 2008; 65: 935-944.
68. SPONHEIM J, POLLHEIMER J, OLSEN T, BALOGH J, HAMMARSTRÖM C, LOOS T, KASPRZYCKA M, SØRENSEN DR, NILSEN HR, KÜCHLER AM, VATN MH, HARALDSEN G. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol 2010; 177: 2804-2815.
69. ITO H. IL-6 and Crohn's disease. Curr Drug Targets Inflamm Allergy 2003; 2: 125-130.
70. JA, BOOTH AJ, LU G, WOOD SC, PINSKY DJ, BISHOP DK. Critical role of IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection. Am J Transplant 2009; 9: 1773-1783.
71. LUCKETT-CHASTAIN LR, GALLUCCI RM. Interleukin (IL)-6 modulates transforming growth factor -beta expression in skin and dermal fibroblasts from IL-6-deficient mice. Br J Dermatol 2009; 161: 237-248.
72. FICHTNER-FEIGL S, STROBER W, KAWAKAMI K, PURI RK, KITANI A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006; 12: 99-106.
73. SANCHEZ-MUÑOZ F, DOMINGUEZ-LOPEZ A, YAMAMOTOFURUSHO JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008; 14: 4280-4288.
74. THEISS AL, SIMMONS JG, JOBIN C, LUND PK. Tumor Necrosis Factor (TNF) a Increases Collagen Accumulation and Proliferation in Intestinal Myofibroblasts via TNF Receptor 2. J Biol Chem 2005; 280: 36099-36109.
75. PAUL M, POYAN MEHR A, KREUTZ R. 139 Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86:747-803.
76. HIRASAWA K, SATO Y, HOSODA Y, YAMAMOTO T, HANAI H. Immunohistochemical localization of angiotensin II receptor and local renin-angiotensin system in human colonic mucosa. J Histochem Cytochem 2002; 50: 275-282.
77. BADER M. Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 2010; 50: 439-465.
78. RUIZ-ORTEGA M, RUPEREZ M, ESTEBAN V, RODRÍGUEZ-VITA J, SÁNCHEZ-LÓPEZ E, CARVAJAL G, EGIDO J. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transpl 2006; 21: 16-20.
79. JASZEWSKI R, TOLIA V, EHRINPREIS MN, BODZIN JH, PELEMAN RR, KORLIPARA R, WEINSTOCK JV. Increased colonic mucosal angiotensin I and II concentration in Crohn's colitis. Gastroenterology 1990; 98: 1543-1548.
80. INOKUCHI Y, MOROHASHI T, KAWANA I, NAGASHIMA Y, KIHARA M, UMEMURA S. Amelioration of 2,4,6-trinitrobenzene sulphonic acid induced colitis in angiotensinogen gene knockout mice. Gut 2005; 54: 349-356.
81. D WENGROWER, G ZANNINELLI, O PAPPO, G LATELLA, M SESTIERI, A. VILLANOVA, Y FAITELSON, M PINES, E GOLDIN. Prevention of fibrosis in experimental colitis by captopril: the role of TGFß1. Inflamm Bowel Dis 2004; 10: 536-545.
82. WENGROWER D, ZANNINELLI G, LATELLA G, NECOZIONE S, METANES I, ISRAELI E, LYSY J, PINES M, PAPO O, GOLDIN E. Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. Can J Gastroenterol 2012; 26: 33-39.
83. VAN DER FLIER A, SONNENBERG A. Function and interactions of integrins. Cell Tissue Res 2001; 305: 285-298.
84. MARGADANT C, SONNENBERG A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep 2010; 11: 97-105.
85. TSANG CK, QI H, LIU LF, ZHENG XF. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007; 12: 112-124.
86. WANG S, WILKES MC, LEOF EB, HIRSCHBERG R. Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 2010; 298: F142-F149.
87. POULALHON N, FARGE D, ROOS N, TACHEAU C, NEUZILLET C, MICHEL L, MAUVIEL A, VERRECCHIA F. Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin. A direct role as an antifibrotic agent? J Biol Chem 2006; 281: 33045-33052.
88. OSMAN B, AKOOL EL-S, DOLLER A, MÜLLER R, PFEILSCHIFTER J, EBERHARDT W. Differential modulation of the cytokine-induced MMP-9/TIMP-1 protease-antiprotease system by the mTOR inhibitor rapamycin. Biochem Pharmacol 2011; 81: 134-143.
89. LIEBERTHAL W, LEVINE JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009; 20: 2493-2502.
90. XU HE, LAMBERT MH, MONTANA VG, PLUNKET KD, MOORE LB, COLLINS JL, OPLINGER JA, KLIEWER SA, GAMPE RT, MCKEE DD, MOORE JT, WILLSON TM. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 2001; 98: 13919-13924.
91. ROUSSEAUX C, DESREUMAUX P. The peroxisome-proliferator-activated gamma receptor and chronic inflammatory bowel disease (PPARgamma and IBD). J Soc Biol 2006; 200: 121-131.
92. ZHAO C, CHEN W, YANG L, CHEN L, STIMPSON SA, DIEHL AM. PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 2006; 350: 385-391.
93. ZHANG GY, CHENG T, ZHENG MH, YI CG, PAN H, LI ZJ, CHEN XL, YU Q, JIANG LF, ZHOU FY, LI XY, YANG JQ, CHU TG, GAO WY. Activation of peroxisome proliferator-activated receptor-gamma inhibits transforming growth factor-beta1 induction of connective tissue growth factor andextracellular matrix in hypertrophic scar fibroblasts in vitro. Arch Dermatol Res 2009; 301: 515-522.
94. LUND PK, RIBY RJ. What are the mechanisms of fibrosis in IBD? Inflamm Bowel Dis 2008; 14: S127-S128.
95. LATELLA G, FIOCCHI C, CAPRILI R. News from the "5th International Meeting on Inflammatory Bowel Diseases" CAPRI 2010. J Crohns Colitis 2010; 4: 690-702.
96. CAPRILLI R, LATELLA G, FRIERI G. Treatment of inflammatory bowel diseases: to heal the wound or to heal the sick? J Crohns Colitis 2012; 6: 621-625.
97. LATELLA G, CAPRILLI R, TRAVIS S. In favour of early surgery in Crohn's disease: a hypothesis to be tested. J Crohn Colitis 2011: 5; 1-4.
98. VAN ASSCHE G, DIGNASS A, REINISCH W, VAN DER WOUDE CJ, STURM A, DE VOS M, GUSLANDI M, OLDENBURG B, DOTAN I, MARTEAU P, ARDIZZONE A, BAUMGART DC, D'HAENS G, GIONCHETTI P, PORTELA F, VUCELIC B, SÖDERHOLM J, ESCHER J, KOLETZKO S, KOLHO KL, LUKAS M, MOTTET C, TILG H, VERMEIRE S, CARBONNEL F, COLE A, NOVACEK G, REINSHAGEN M, TSIANOS E, HERRLINGER K, OLDENBURG B, BOUHNIK Y, KIESSLICH R, STANGE E, TRAVIS S, LINDSAY J; EUROPEAN CROHN'S AND COLITIS ORGANISATION (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohn Colitis 2010; 4: 63-101.
99. DIGNASS A, VAN ASSCHE G, LINDSAY JO, LÉMANN M, SÖDERHOLM J, COLOMBEL JF, DANESE S, D'HOORE A, GASSULL M, GOMOLLÓN F, HOMMES DW, MICHETTI P, O'MORAIN C, ORESLAND T, WINDSOR A, STANGE EF, TRAVIS SP; EUROPEAN CROHN'S AND COLITIS ORGANISATION (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Current management. J Crohn Colitis 2010: 4: 28-62.
100. SAMIMI R, FLASAR MH, KAVIC S, TRACY K, CROSS RK. Outcome of medical treatment of stricturing and penetrating Crohn's disease: a retrospective study. Inflamm Bowel Dis 2010; 16: 1187-1194.
101. PAPI C, FESTA V, FAGNANI C, STAZI A, ANTONELLI G, MORETTI A, KOCH M, CAPURSO L. Evolution of clinical behaviour in Crohn's disease: predictive factors of penetrating complications. Digest Liver Dis 2005; 37: 247-253.
102. SZABÒ H, FIORINO G, SPINELLI A, ROVIDA S, REPICI A, MALESCI AC, DANESE S. Review article: anti-fibrotic agents for the treatment of Crohn's disease-lessons learnt from other diseases. Aliment Pharmacol Ther 2010; 31: 189-201.
103. VAGLIO A, PALMISANO A, CORRADI D, SALVARANI C, BUZIO C. Retroperitoneal fibrosis: evolving concepts. Rheum Dis Clin North Am 2007; 33: 803-817.
104. BADEA I, TAYLOR M, ROSENBERG A, FOLDVARI M. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology 2009; 48: 213-221.
105. ROGLIANI P, MURA M, ASSUNTA PORRETTA M, SALTINI C. New perspectives in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2008; 2: 75-93.
106. GRAHAM MF, WILLEY A, ADAMS J, DIEGELMANN RF. Corticosteroids increase procollagen gene expression, synthesis, and secretion by human intestinal smooth muscle cells. Gastroenterology 1995; 109: 1454-1461.
107. VIDELA S, VILASECA J, MEDINA C, MOURELLE M, GUARNER F, SALAS A, MALAGELADA JR. Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis. J Pharmacol Exp Ther 2006; 316: 940-945.
108. WARNATZ K, KESKIN AG, UHL M, SCHOLZ C, KATZENWADEL A, VAITH P, PETER HH, WALKER UA. Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis 2005; 64: 828-833.
109. Dheda K, Lalloo UG, Cassim B, Mody GM. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004; 23: 306-309.
110. PEYRIN-BIROULET L, DELTENRE P, ARDIZZONE S, D'HAENS G, HANAUER SB, HERFARTH H, LÉMANN M, COLOMBEL JF. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis .Am J Gastroenterol 2009; 104: 2089-2096.
111. VASILOPOULOS S, KUGATHASAN S, SAEIAN K, EMMONS JE, HOGAN WJ, OTTERSON MF, ET AL. Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn's disease. Am J Gastroenterol 2000; 95: 2503 (A315).
112. TOY LS, SCHERL EJ, KORNBLUTH A, KORNBLUTH A, MARION JF, GREENSTEIN AJ, ET AL. Complete bowel obstruction following initial response to infliximab therapy for Crohn's disease: A series of a newly described complication. Gastroenterology 2000; 118(Suppl 2, Part 1): A569 (2974).
113. LICHTENSTEIN GR, OLSON A, TRAVERS S, DIAMOND RH, CHEN DM, PRITCHARD ML, FEAGAN BG, COHEN RD, SALZBERG BA, HANAUER SB, SANDBORN WJ. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 2006; 101: 1030-1038.
114. DI SABATINO A, PENDER SL, JACKSON CL, PROTHERO JD, GORDON JN, PICARIELLO L, ROVEDATTI L, DOCENA G, MONTELEONE G, RAMPTON DS, TONELLI F, CORAZZA GR, MACDONALD TT. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 2007; 133: 137-149.
115. DI SABATINO A, CICCOCIOPPO R, BENAZZATO L, STURNIOLO GC, CORAZZA GR. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients. Aliment Pharmacol Ther 2004; 19: 1019-1024.
116. HANAUER SB, FEAGAN BG, LICHTENSTEIN GR, MAYER LF, SCHREIBER S, COLOMBEL JF, RACHMILEWITZ D, WOLF DC, OLSON A, BAO W, RUTGEERTS P; ACCENT I STUDY GROUP. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
117. LICHTENSTEIN GR, YAN S, BALA M, BLANK M, SANDS BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-869.
118. SCHNITZLER F, FIDDER H, FERRANTE M, NOMAN M, ARIJS I, VAN ASSCHE G, HOFFMAN I, VAN STEEN K, VERMEIRE S, RUTGEERTS P. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
119. BOUGUEN G, PEYRIN-BIROULET L. Surgery for adult Crohn's disease: what is the actual risk? Gut 2011; 60: 1178-1181.
120. SORRENTINO D. Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far? Digestion 2008; 77: 38-47.
121. VAN ASSCHE G, VERMEIRE S, RUTGEERTS P. The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol 2010; 7: 79-85.
122. DANESE S. Inflammation and the mucosal microcirculation in inflammatory bowel disease: the ebb and flow. Curr Opin Gastroenterol 2007; 23: 384-389.
123. DANESE S. Nonimmune cells in inflammatory bowel disease: from victim to villain", Trends Immunol 2008; 29: 555-564.
124. GHOSH S, PANACCIONE R. Anti-adhesion olecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol 2010; 3: 239-258.
125. KOBOZIEV I, KARLSSON F, ZHANG S, GRISHAM MB. Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical data into new drug therapies. Inflamm Bowel Dis 2011; 17: 1229-1245.
126. KULKARNI AB, HUH CG, BECKER D, GEISER A, LYGHT M, FLANDERS KC, ROBERTS AB, SPORN MB, WARD JM, KARLSSON S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993; 90: 770-774.
127. NOMURA M, LI E. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature 1998; 393: 786-790.
128. YANG X, LI C, HU X, DENG C. The tumor suppressor Smad4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc Natl Acad Sci USA 1998; 95: 3667-3672.
129. YANG X, LETTERIO JJ, LECHLEIDER RJ, CHEN L, HAYMAN R, GU H, ROBERTS AB, DENG C. Targeted disruption of Smad3 results in impaired mucosal immunity and diminished T cell responsiveness to TGFbeta. EMBO J 1999; 18: 1280-1291.
130. DATTO MB, FREDERICK JP, PAN L, BORTON AJ, ZHUANG Y, WANG XF. Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol Cell Biol 1999; 19:2 495-2504.
131. ZHU Y, RICHARDSON JA, PARADA LF, GRAFF JM. Smad3 mutant mice develop metastatic colorectal cancer. Cell 1998; 94: 703-714.
132. HAWINKELS LJ, TEN DIJKE P. Exploring anti-TGF-β therapies in cancer and fibrosis. Growth Factors 2011; 29: 140-152.
133. VARGA J, PASCHE B. Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis. Curr Opin Rheumatol 2008; 20: 720-728.
134. HAHM K, LUKASHEV ME, LUO Y, YANG WJ, DOLINSKI BM, WEINREB PH, SIMON KJ, CHUN WANG L, LEONE DR, LOBB RR, MCCRANN DJ, ALLAIRE NE, HORAN GS, FOGO A, KALLURI R, SHIELD CF 3RD, SHEPPARD D, GARDNER HA, VIOLETTE SM. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol 2007; 170: 110-125.
135. HORAN GS, WOOD S, ONA V, LI DJ, LUKASHEV ME, WEINREB PH, SIMON KJ, HAHM K, ALLAIRE NE, RINALDI NJ, GOYAL J, FEGHALI-BOSTWICK CA, MATTESON EL, O'HARA C, LAFYATIS R, DAVIS GS, HUANG X, SHEPPARD D, VIOLETTE SM. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008; 177: 56-65.
136. SULLIVAN BP, WEINREB PH, VIOLETTE SM, LUYENDYK JP. The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis. Am J Pathol. 2010; 177: 2837-2849.
137. KATSUMOTO TR, VIOLETTE SM, SHEPPARD D. Blocking TGFβ via Inhibition of the αvβ6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease. Int J Rheumatol 2011; 2011: 208-219.
138. PANGANIBAN RA, DAY RM. Hepatocyte growth factor in lung repair and pulmonary fibrosis. Acta Pharmacol Sin 2011; 32: 12-20
139. LIU Y, YANG J. Hepatocyte growth factor: new arsenal in the fights against renal fibrosis? Kidney Int 2006; 70: 238-240.
140. WEISKIRCHEN R, MEURER SK, GRESSNER OA, HERRMANN J, BORKHAM-KAMPHORST E, GRESSNER AM. BMP-7 as antagonist of organ fibrosis. Front Biosci 2009; 14: 4992-5012.
141. BAGHY K, IOZZO RV, KOVALSZKY I. Decorin-TGFβ axis in hepatic fibrosis and cirrhosis. J Histochem Cytochem 2012; 60: 262-268.
142. MA FY, SACHCHITHANANTHAN M, FLANC RS, NIKOLICPATERSON DJ. Mitogen activated protein kinases in renal fibrosis. Front Biosci 2009;1:171-187.
143. DISTLER JH, DISTLER O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology 2008; 47(Suppl 5): v10-1.
144. GORDON J, SPIERA R. Imatinib and the treatment of fibrosis: recent trials and tribulations. Curr Rheumatol Rep 2011; 13: 51-58.
145. PHANISH MK, WINN SK, DOCKRELL ME. Connective tissue growth factor-(CTGF, CCN2)-a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp Nephrol 2010; 114: e83-92.
146. HUANG G, BRIGSTOCK DR. Regulation of hepatic stellate cells by connective tissue growth factor. Front Biosci 2012; 17: 2495-2507.
147. FICHTNER-FEIGL S, YOUNG CA, KITANI A, GEISSLER EK, SCHLITT HJ, STROBER W. IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology 2008; 135: 2003-2013.
148. FICHTNER-FEIGL S, FUSS IJ, YOUNG CA, WATANABE T, GEISSLER EK, SCHLITT HJ, KITANI A, STROBER W. Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol 2007; 178: 5859-5870.
149. URTASUN R, CONDE DE LA ROSA L, NIETO N. Oxidative and nitrosative stress and fibrogenic response. Clin Liver Dis 2008; 12: 769-790.
150. SERRANO-MOLLAR A, CLOSA D, PRATS N, BLESA S, MARTINEZ-LOSA M, CORTIJO J, ESTRELA JM, MORCILLO EJ, BULBENA O. In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats. Br J Pharmacol 2003, 138: 1037-1048.
151. SVEGLIATI-BARONI G, SACCOMANNO S, VAN GOOR H, JANSEN P, BENEDETTI A, MOSHAGE H. Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver 2001; 21: 1-12.
152. RACHMILEWITZ D, KARMELI F, OKON E, BURSZTYN M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 1995; 37: 247-255.
153. SOFRONIADOU S, GOLDSMITH D. Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects. Drug Saf 2011; 34: 97-115.
154. ONG CT, KHOO YT, MUKHOPADHYAY A, DO DV, LIM IJ, AALAMI O, PHAN TT. mTOR as a potential therapeutic target for treatment of keloids and excessive scars. Exp Dermatol 2007; 16: 394-404.
155. KORFHAGEN TR, LE CRAS TD, DAVIDSON CR, SCHMIDT SM, IKEGAMI M, WHITSETT JA, HARDIE WD. Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2009; 41: 562-572.
156. GEISSLER EK, SCHLITT HJ. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int 2010; 78: 1075-1079.
157. PATSENKER E, SCHNEIDER V, LEDERMANN M, SAEGESSER H, DORN C, HELLERBRAND C, STICKEL F. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclospor ine A and tacrolimus in experimental liver fibrosis. J Hepatol 2011; 55: 388-398.
158. NEEF M, LEDERMANN M, SAEGESSER H, SCHNEIDER V, REICHEN J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006; 45: 786-796.
159. MASSEY DC, BREDIN F, PARKES M. Case report Use of sirolimus (rapamycin) to treat refractory Crohn's disease Gut 2008; 57: 1294-1296.
160. DUMORTIER J, LAPALUS MG, GUILLAUD O, PONCET G, GAGNIEU MC, PARTENSKY C, SCOAZEC JY. Everolimus for refractory Crohn's disease: a case report. Inflamm Bowel Dis 2008; 14: 874-877.
161. REINISCH W, PANÉS J, LÉMANN M, SCHREIBER S, FEAGAN B, SCHMIDT S, STURNIOLO GC, MIKHAILOVA T, ALEXEEVA O, SANNA L, HAAS T, KOROM S, MAYER H. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 2008; 103: 2284-2292.
162. NAN YM, HAN F, KONG LB, ZHAO SX, WANG RQ, WU WJ, YU J. Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. Scand J Gastroenterol 2011; 46: 358-369.
163. KAPOOR M, MCCANN M, LIU S, HUH K, DENTON CP, ABRAHAM DJ, LEASK A. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 2009; 60: 2822-2829.
164. WEI J, GHOSH AK, SARGENT JL, KOMURA K, WU M, HUANG QQ, JAIN M, WHITFIELD ML, FEGHALI-BOSTWICK C, VARGA J. PPARγ downregulation by TGFβ in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010; 5: e13778.
165. WU M, MELICHIAN DS, CHANG E, WARNER-BLANKENSHIP M, GHOSH AK, VARGA J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 2009; 174: 519-533.
166. KAWAI T, MASAKI T, DOI S, ARAKAWA T, YOKOYAMA Y, DOI T, KOHNO N, YORIOKA N. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 2009; 89: 47-58.
167. AOKI Y, MAENO T, AOYAGI K, UENO M, AOKI F, AOKI N, NAKAGAWA J, SANDO Y, SHIMIZU Y, SUGA T, ARAI M, KURABAYASHI M. Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand,suppresses bleomycin-induced acute lung injury and fibrosis. Respiration 2009; 77: 311-319.
168. YANG L, STIMPSON SA, CHEN L, WALLACE HARRINGTON W, ROCKEY DC. Effectiveness of the PPARγ agonist, GW570, in liver fibrosis. Inflamm Res 2010; 59: 1061-1071.
169. RAVI A, GARG P, SITARAMAN SV. Matrix metalloproteinases in inflammatory bowel disease: boon or a bane? Inflamm Bowel Dis 2007; 13: 97-107.
170. CLUTTERBUCK AL, ASPLIN KE, HARRIS P, ALLAWAY D, MOBASHERI A. Targeting matrix metalloproteinases in inflammatory conditions. Curr Drug Targets 2009; 10: 1245-1254.
171. SHYU KG, WANG BW, CHEN WJ, KUAN P, HUNG CR. Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta1 in cultured cardiac fibroblasts. Eur J Heart Fail 2010; 12: 219-226.
172. BURKE JP, WATSON RW, MURPHY M, DOCHERTY NG, COFFEY JC, O'CONNELL PR. Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor beta1-mediated activation of intestinal fibroblasts. Br J Surg 2009; 96: 541-551.
173. ABE Y, MURANO M, MURANO N, MORITA E, INOUE T, KAWAKAMI K, ISHIDA K, KURAMOTO T, KAKIMOTO K, OKADA T, NARABAYASHI K, UMEGAKI E, HIGUCHI K. Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast/myofibroblast apoptosis in the regeneration/healing process from TNBS-induced colitis. Dig Dis Sci 2012; 57: 335-344.
174. SAKAMOTO I, ITO Y, MIZUNO M, SUZUKI Y, SAWAI A, TANAKA A, MARUYAMA S, TAKEI Y, YUZAWA Y, MATSUO S. Lymphatic vessels develop during tubulointerstitial fibrosis. Kidney Int 2009; 75: 828-838.
175. DANESE S. Role of the vascular and lymphatic endothelium in the pathogenesis of inflammatory bowel disease: 'brothers in arms'. Gut 2011; 60: 998-1008.
176. SCALDAFERRI F, VETRANO S, SANS M, ARENA V, STRAFACE G, STIGLIANO E, REPICI A, STURM A, MALESCI A, PANES J, YLA-HERTTUALA S, FIOCCHI C, DANESE S. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009; 136: 585-595.
177. HERING NA, FROMM M, SCHULZKE JD. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol 2012; 590: 1035-1044.
178. NEURATH MF, TRAVIS SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012; 61: 1619-1635.
179. HARTMANN P, CHEN WC, SCHNABL B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol 2012; 3: 402.
180. YANG S, BANERJEE S, DE FREITAS A, SANDERS YY, DING Q, MATALON S, THANNICKAL VJ, ABRAHAM E, LIU G. Participation of miR-200 in pulmonary fibrosis. Am J Pathol 2012; 180: 484-493.
181. WANG B, KOH P, WINBANKS C, COUGHLAN MT, MCCLELLAND A, WATSON A, JANDELEIT-DAHM K, BURNS WC, THOMAS MC, COOPER ME, KANTHARIDIS P. miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes 2011; 60: 280-287.
182. CHEN Y, GE W, XU L, QU C, ZHU M, ZHANG W, XIAO Y. miR-200b is involved in intestinal fibrosis of Crohn's disease. Int J Mol Med 2012; 29: 601-606.
183. PEKOW JR, KWON JH. MicroRNAs in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 187-193.